JD Supra28d
The Precedent: Federal Circuit Adds Clarity to Personal Jurisdiction and Obviousness-Type Double Patenting Analyses in Regeneron Pharms
In this edition of The Precedent, we outline the decision in Regeneron Pharms., Inc. v. Mylan Pharms. Inc. In Regeneron Pharms., Inc. v. Mylan Pharms. Inc., the ...
JD Supra1mon
Maximizing Patent Term in the United States: Patent Term Adjustment, Patent Term Extension, and the Evolving Law of Obviousness-Type Double Patenting
Under U.S. law, most patents are limited to a term of 20 years from the earliest nonprovisional filing date. However, Patent Term Adjustment (PTA) and Patent Term Extension (PTE) can be used in ...